Immunocore Holdings (IMCR) Assets Average (2020 - 2026)
Immunocore Holdings (IMCR) posted Assets Average of $1.1 billion for Q1 2026, down 1.4% sequentially from $1.1 billion in Q4 2025, and up 5.0% YoY from $1.0 billion in Q1 2025.
Analysis
Immunocore Holdings (IMCR) Assets Average (2020 - 2026) Analysis & Trends
Immunocore Holdings has reported Assets Average for 5 years, with the latest figure at $1.1 billion in Q1 2026.
- Quarterly Assets Average rose 5.0% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 5.0% YoY) and the FY2025 annual result came in at $1.0 billion, up 29.27% from the prior year.
- Assets Average retreated to $1.1 billion in Q1 2026 per IMCR's latest filing, from $1.1 billion in the prior quarter.
- Over five years, Assets Average peaked at $1.1 billion in Q3 2025 and troughed at $517.5 million in Q4 2022.
- A 4-year average of $974.4 million and a median of $1.1 billion in 2024 frame the typical range for Assets Average.
- The widest YoY moves for Assets Average: up 28.07% in 2025, down 3.61% in 2025.
- Over 4 years, Assets Average stood at $517.5 million in 2022, then surged by 102.35% to $1.0 billion in 2024, then advanced by 3.61% to $1.1 billion in 2025, then retreated by 1.4% to $1.1 billion in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $1.1 billion, $1.1 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Immunocore Holdings | 1.85 Bn | 965.54 Mn | 114.84 Mn | 1.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Bn |
| Mar 31, 2026 | 1.07 Bn |
| Dec 31, 2025 | 1.08 Bn |
| Sep 30, 2025 | 1.09 Bn |
| Jun 30, 2025 | 1.06 Bn |
| Mar 31, 2025 | 1.02 Bn |
| Dec 31, 2024 | 1.05 Bn |
| Sep 30, 2024 | 1.05 Bn |
| Jun 30, 2024 | 1.01 Bn |
| Mar 31, 2024 | 795.49 Mn |
| Dec 31, 2022 | 517.45 Mn |
| Dec 31, 2020 | 249.54 Mn |